Oncologic outcomes and renal function preservation after stereotactic ablative body radiotherapy versus radiofrequency ablation in stage I renal cell carcinoma.
Yoo YJ, Jiyoon L, Park KJ, Song C, Kim YJ, Kim YS.
Abstract
PurposeThis study compared stereotactic ablative body radiotherapy (SABR) and radiofrequency ablation (RFA) in patients with biopsy-proven stage I renal cell carcinoma (RCC), focusing on oncologic outcomes and renal function outcomes.MethodsPatients with stage I RCC treated with CyberKnife-based SABR or percutaneous RFA between 2009 and 2024 were retrospectively analyzed. Renal function was assessed using serial changes in estimated glomerular filtration rate (eGFR). Inverse probability of treatment weighting (IPTW) was applied to adjust for baseline imbalances.ResultsWith a median follow-up of 46.3 months, 123 patients (SABR, n = 54; RFA, n = 69) were analyzed. Patients treated with SABR were significantly older (p = 0.002), and had larger tumors (p ConclusionIn patients with stage I RCC, SABR may be considered a local treatment option with oncologic and renal outcomes comparable to those of RFA.